home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  December 18, 2024
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries

Nutri-Pharm Bioscientific Info Enterprise Canada

Barberry House 1440 Barberry Drive
Port Coquitlam
Canada

Phone: 6049458408
Fax: 16049419022
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Current Candidates for Pharma and Nutri-pharm are as ff.:

1. PNA-Carriers (cf. U. Tyslents, I. Siebierska and J. Trylska. 2023. Eur Biophys J. 52: 533-544) with anti-microbials the first foremost application to this revolutionary genetically regulatory modifying (GRO) technology with an emphasis on pharmaceuticals discovery or applications. This will be revolutionary in finding new avenues to limit use of antibiotics (Abs) and to counter growing resistance amongst pathogens and instead turn to these drugs as well as growth feed additives.

2. PNA-Carriers to enhance vaccines against Streptococcus pneumoniae tested with a system of microbial targets or pathogens, their production of antigens (Ags), riboflavin metabolite for opsonization enhancement from IgG with presentation of antigens (Ags) or microbial riboflavin metabolite by MR1 molecules, that is, MHC class Ib-related molecules, activates mucosa-associated invariant T (MAIT) cells (e. g. nasopharyngeal openings in cows and the liver) as would be the case with the application of vaccines and induced humoral adaptive antibacterial immunity (cf. C. Boulouis et al. 2020. The J of Immun. 205: 67-77) to treat lung-associated diseases as pneumonia in cows or beef lot animals direct applied (DA) by spray inhaler.

3. PNA-Carriers are prebiotics to the lower gut to effect improved colon and caecal digestion of fibre and protein residual to upper tract digestion including production of butyrate amongst the VFAs and ammonia for the microbial ecosystem there for digestion and immune function and health to the animal. 

4. PNA-Carriers to enhance endocrinological growth releasing hormone (GRH) in the CNS and growth hormone (GH) and prolactin for both meat and milk (there are also other endocrine hormones such as CCK and somatostatin from the gut organ that have similar functions) which will also along with antimicrobials lead to use of less antibiotics (Abs) as growth feed additives.

5. PNA-Carriers to enhance VitD2,3 metabolism with applications in osteoporosis, a cure perhaps in the long run, and treatment of cows predisposed to milk fever, as with Ca2+ supplements as in the theory of Flores (2021) regards the drug synthesis of VitD2-agonists (VitD-As) to 'gently' use pharma to antagonize FBI of VitD activation with an agonist. 

 

No doubt as of just the end of the year 2024 we will hear more from our key researchers who we have taken an interest in their work and wish them the Best of the Season 2024-25 and Cheers always! -SkyeBlue

 

D. A. Flores

Skye Blue (SB) Internet

Port Coquitlam, BC  V3B 1G3

Canada

Barberry House, Port Coquitlam BC Canada

V3B 1G3; 16049458408; skyebluepublications@aim.com

W: https://www.doitfaxit.biz; W: https://www.skyebluesbinternet.com; W: https://www.energeneconsulting.com; W: https://www.brand.site/skyebluewebstore; W: https://www.foodiesbuffetonboardcuisine.com; W: https://www.lechezpanceteriaetcafe.com; W: https://www.hum-molgen.org (DE) 



Selected Categories:
Product Company   Service Company
Consulting
- General
- Research
Contract
- Services
Professional
- Communications

Last update of this entry: December 08, 2024

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.